Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?

Purpose Given the biological differences between females and males, sex-specific evaluations should be carried out to obtain better cancer prevention, diagnosis, and treatment strategies. To this purpose, our aim was to evaluate sex differences for toxicity in a cohort of colorectal cancer (CRC) patients undergoing chemotherapy. Methods We performed a retrospective study in 329 CRC patients. Differences between males and females were tested performing the Mann-Whitney U test or the Fisher exact test. Multivariate logistic regression models were computed to evaluate the association between sex and risk of chemotherapy agent-related toxicity. Results According association sex toxicity, significant differences were observed in the median number of episodes of nausea ( p = 0.044), vomit ( p = 0.007), heartburn ( p = 0.022), thrombocytopenia ( p = 0.005), mucositis ( p = 0.024). Moreover, statistically significant differences between males and females were observed in the distribution of the highest toxicity grades of nausea ( p = 0.024), heartburn ( p = 0.016), and thrombocytopenia ( p = 0.034). Females have an increased risk of vomit ( p = 0.002), alopecia ( p = 0.035), heartburn ( p = 0.005), mucositis ( p = 0.003), and lower risk for thrombocytopenia ( p = 0.005). Conclusion According to the association of sex chemotherapy agent-related toxicities, females resulted on average at a significant increased risk of more common adverse events (constipation, dysgeusia, alopecia, heartburn, vomit, asthenia, nausea, pain events, and mucositis). Sex-tailored CRC chemotherapy treatment is necessary to obtain efficacy avoiding toxicity, based on patients’ biological and genetic characteristics, a vision that would change CRC setting, a stable disease but still orphan of a real tailored approach.